Singapore-based biotherapeutics startup Hummingbird Bioscience has raised US$19 million in a series B round co-led by Korean investors Mirae Asset Venture Investment and GNTech Venture Capital. New backers Delian Capital, Mirae Asset Capital, DAValue-GiltEdge, HB Investment, Wooshin Venture Investment, and Kiwoom Investment-Shinhan Capital also participated in the round, alongside existing investors Heritas Capital and Seeds Capital. Hummingbird focuses on the…